Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
biotech
national top stories
clinical trials
san francisco blog main
startups
20/20 healthcare partners
ally bridge group
amgen ventures
amyotrophic lateral sclerosis
anthony despasqua
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
casdin capital
christian angermayer
crispr
david walt
deals
diabetic nephropathy
diagnostics
dolby family ventures
duchenne muscular dystrophy
dyne therapeutics
enclear therapies
eventide asset management
facioscapulohumeral muscular dystrophy
feng zhang
financing
focal segmental glomerulosclerosis
funding
gene editing
What
diseases
4
×
medicines
bio
develop
drug
genetic
ipo
new
raised
ago
analysis
associated
biotech
biotechs
bring
companies
company
considering
create
crispr
data
device
diagnostic
dialysis
disease
drugs
dyne
early
editing
employing
enclear
expected
experimental
eyes
fix
gene
goldfinch
harmful
having
heats
Language
unset
Current search:
diseases
×
boston
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
